Emcure Consolidates Gennova Ownership; Sharpens Focus on Biologics; Samit Mehta Leads the Next Phase of Growth
Pune: Emcure Pharmaceuticals Limited (BSE: 544210, NSE: EMCURE) today announced the consolidation of its shareholding in biopharma subsidiary Gennova Biopharmaceuticals Limited (“Gennova”), alongside a leadership transition, as it sharpens its focus as a biologics and biosimilars company. Emcure is acquiring the entire 12.05% minority stake in Gennova held by Dr. Sanjay Singh and others, taking its ownership to 100% and making Gennova a wholly owned subsidiary. Gennova will be led by Samit Mehta and will focus on its biologics franchise — Elaxim®/TENECTASE®, Vintor®, Xgrast®/PEGEX® and Hamsyl® — biosimilars development, and adjacent
